Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

P53 Downregulation-Based Strategy to Protect Genomic Integrity from Radiation Therapy

Hang Su, Mei-Jun Long, MD PhD, Joel E Michalek, PhD, Michael Weil, PhD, Chul S Ha, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139137

Published: 2020

Journal Articles

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Chul S. Ha, MD, Hongli Li, MS, Heiko Schoder, MD, Chelsea C Pinnix, MD, Elizabeth Brem, MD, Nancy L. Bartlett, MD, Andrew M. Evens, DO, MSc, Eric D. Hsi, MD, Lisa M. Rimsza, MD, John P. Leonard, MD, Brad S Kahl, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Louis S. Constine, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2018-99-113133

Published: 2018

Journal Articles

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

Farhad Ravandi, MD, Megan Othus, PhD, Susan O'Brien, MD, Stephen J. Forman, MD, Chul S. Ha, MD, Jeffrey Y. C. Wong, MD, Martin S Tallman, MD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Geoffrey L. Uy, MD, Uma Borate, MD, Partow Kebriaei, MD, Laura Kingsbury, MRT, Hagop M. Kantarjian, MD, Jerald P. Radich, Harry P. Erba, MD PhD, Frederick R. Appelbaum, MD

Blood (2015) 126 (23): 796.

https://doi.org/10.1182/blood.V126.23.796.796

Published: 2015

Journal Articles

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

Chul S. Ha, MD, Joel Michalek, PhD, Richard Elledge, MD, Kevin R. Kelly, MD, PhD, Suthakar Ganapathy, PhD, Hang Su, PhD, Carol Jenkins, RN, BSN, Athanassios Argiris, MD, Ronan Swords, MD, PhD, Tony Y. Eng, MD, Anand Karnad, MD, Richard Crownover, MD, PhD, Gregory P Swanson, MD, Martin Goros, M.S., Brad H Pollock, MPH, PhD, Zhi-Min Yuan, MD, PhD

Blood (2014) 124 (21): 4809.

https://doi.org/10.1182/blood.V124.21.4809.4809

Published: 2014

Journal Articles

A Novel p53-Based Strategy for Protection of Bone Marrow and Gastrointestinal (GI) Track From Total Body Irradiation (TBI)-Induced Damage.

Chul S. Ha, MD, Suthakar Ganapathy, Ph.D., Zhi Min Yuan, M.D., Ph.D.

Blood (2010) 116 (21): 1454.

https://doi.org/10.1182/blood.V116.21.1454.1454

Published: 2010

Journal Articles

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcos de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1135.

https://doi.org/10.1182/blood.V106.11.1135.1135

Published: 2005

Journal Articles

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Partow Kebriaei, MD, Rima M. Saliba, PhD, Carrie Ma, Cindy Ippoliti, PharmD, Daniel R. Couriel, MD, Marcus de Lima, MD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, James L. Gajewski, MD, Chul S. Ha, MD, Richard E. Champlin, MD, Issa F. Khouri, MD

Blood (2005) 106 (11): 1803.

https://doi.org/10.1182/blood.V106.11.1803.1803

Published: 2005

NARROW

P53 Downregulation-Based Strategy to Protect Genomic Integrity from Radiation Therapy

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

A Novel p53-Based Strategy for Protection of Bone Marrow and Gastrointestinal (GI) Track From Total Body Irradiation (TBI)-Induced Damage.

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

P53 Downregulation-Based Strategy to Protect Genomic Integrity from Radiation Therapy

Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis

Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60

P53 Based Strategy to Reduce Hematological Toxicity of Chemotherapy: Emerging Support from a Phase II Trial

A Novel p53-Based Strategy for Protection of Bone Marrow and Gastrointestinal (GI) Track From Total Body Irradiation (TBI)-Induced Damage.

Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).

The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only